1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,220 | 1,280 | 10:34 | |
| 1,220 | 1,280 | 10:16 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | MIRA PHARMACEUTICALS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 26.11. | RECIPHARM AB: Telomir and Mira Pharmaceuticals advance through key development milestones with Recipharm support | 1 | Cision News | ||
| 13.11. | MIRA PHARMACEUTICALS, INC. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 24.10. | MIRA Pharmaceuticals Initiates Multiple Ascending Dose Phase 1 Study of Oral Ketamir-2 and Selects Chemotherapy-Induced Neuropathic Pain as Lead Phase 2a Indication | 297 | ACCESS Newswire | Advancing toward Phase 2a clinical evaluation in chemotherapy-related pain, a condition with no approved treatments and potential for FDA Fast Track consideration MIAMI, FLORIDA / ACCESS Newswire /... ► Artikel lesen | |
| 23.10. | MIRA PHARMACEUTICALS, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 16.10. | Mira Pharmaceuticals stock soars after positive pain treatment study results | 12 | Investing.com | ||
| MIRA PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 16.10. | Morning Market Movers: rYojbaba, Linkage Global, MIRA Pharmaceuticals, Fossil Group See Big Swings | 514 | AFX News | LOWELL (dpa-AFX) - At 7:45 a.m. ET on Thursday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| 16.10. | MIRA Pharmaceuticals Announces Oral Mira-55 Outperformed Injected Morphine in Normalizing Pain and Reducing Inflammation, Supporting Its Planned IND for Chronic Inflammatory Pain | 314 | ACCESS Newswire | Findings show oral Mira-55 fully normalized pain and significantly reduced inflammation, supporting IND plans and reinforcing MIRA's position in a $70 billion non-opioid pain market. MIAMI, FLORIDA... ► Artikel lesen | |
| 16.10. | Why Mira Pharmaceuticals Shares Rose 69% After Hours? | 24 | Benzinga.com | ||
| 15.10. | MIRA PHARMACEUTICALS, INC. - 8-K, Current Report | 25 | SEC Filings | ||
| 30.09. | MIRA Pharmaceuticals schließt Übernahme von SKNY ab und stärkt Finanzposition durch 5 Millionen US-Dollar | 13 | Investing.com Deutsch | ||
| 30.09. | MIRA Pharmaceuticals completes acquisition of SKNY Pharmaceuticals | 3 | Investing.com | ||
| 30.09. | MIRA Pharmaceuticals Closes Acquisition of SKNY Pharmaceuticals, Expands Pipeline with SKNY-1 for Obesity and Nicotine Addiction | 284 | ACCESS Newswire | Closing adds $5 million in marketable securities, strengthens financial position, and complements MIRA's advancing programs including Ketamir-2 and MIRA-55 MIAMI, FLORIDA / ACCESS Newswire / September... ► Artikel lesen | |
| 30.09. | MIRA PHARMACEUTICALS, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 22.09. | MIRA Pharmaceuticals reports positive Phase 1 results for pain drug | 7 | Investing.com | ||
| 22.09. | MIRA Pharmaceuticals Announces Favorable Topline Results from Phase 1 SAD Study of Oral Ketamir-2, a Next-Generation Non-Scheduled Ketamine Analog | 209 | ACCESS Newswire | Study demonstrated Ketamir-2 was safe and well tolerated at all dose levels, with a favorable safety and tolerability profile, with no severe or clinically significant adverse effects observed. The... ► Artikel lesen | |
| 22.09. | MIRA PHARMACEUTICALS, INC. - 8-K, Current Report | 3 | SEC Filings | ||
| 16.09. | MIRA Pharmaceuticals Reports Positive PTSD Data Demonstrating Ketamir-2 Restores Normalized Behavior in Stressed Animals | 255 | ACCESS Newswire | MIRA advances Ketamir-2 in the clinic for neuropathic pain while broadening development into neuropsychiatric disorders such as PTSD MIAMI, FLORIDA / ACCESS Newswire / September 16, 2025 / MIRA Pharmaceuticals... ► Artikel lesen | |
| 12.09. | MIRA Pharmaceuticals Shareholders Approve Acquisition of SKNY Pharmaceuticals, Advancing Next-Generation Oral Therapeutic for Obesity and Smoking Cessation | 329 | ACCESS Newswire | SKNY transaction strengthens MIRA pipeline with SKNY-1, a differentiated oral candidate that has demonstrated up to 30% weight loss and nicotine craving reversal in preclinical studies. MIAMI, FL /... ► Artikel lesen | |
| 11.09. | MIRA PHARMACEUTICALS, INC. - 8-K, Current Report | 2 | SEC Filings |
1 2 3 Weiter >>
55 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 82,35 | -0,18 % | BioNTech SE: BioNTech erfüllt Mindestannahmebedingungen im Rahmen des Umtauschangebots für CureVac-Aktien | Mindestannahmebedingung für das Angebot wurde erfüllt; es wurden vor Ablauf der ursprünglichen Angebotsfrist insgesamt 184.071.410 CureVac-Aktien angedient, was etwa 81,74 % der ausgegebenen und im... ► Artikel lesen | |
| EVOTEC | 5,100 | -0,35 % | DAX-Check LIVE: Aurubis, Evotec, Formycon, Infineon, Porsche SE, Siemens Energy im Fokus | Die Erholung an der Börse hat sich zur Wochenmitte nicht fortgesetzt. Der DAX startete zwar mit kleinen Gewinnen in den Tag, rutschte im Verlauf jedoch ins Minus und schloss schließlich bei 23.694 Punkten... ► Artikel lesen | |
| BB BIOTECH | 48,250 | -1,63 % | BB Biotech im Aufwind - Zinswende treibt Biotech-Rally an | US-Zinssenkung belebt den Biotech-Sektor. BB Biotech glänzt mit starkem Quartal, vier Exits und klarer Outperformance gegenüber dem Nasdaq Biotech Index. Seit der ersten Zinssenkung der US-Notenbank... ► Artikel lesen | |
| QIAGEN | 39,415 | -0,18 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Die Profitabilität dürfte 2026 zumindest stabil bleiben... ► Artikel lesen | |
| CUREVAC | 4,348 | -1,58 % | EILMELDUNG: Curevac-Aktie im freien Fall - Anleger fliehen aus dem Wert! | ||
| AMGEN | 268,90 | -0,39 % | Amgen raises dividend by ~6% | ||
| NOVAVAX | 5,701 | -0,56 % | Novavax, Inc. (NVAX): A Bull Case Theory | ||
| STRYKER | 301,20 | +0,27 % | Stryker Appoints Spencer Stiles As President And COO | WASHINGTON (dpa-AFX) - Stryker Corp. (SYK), Thursday announced the appointment of Spencer Stiles as President and Chief Operating Officer of the company, effective January 1, 2026.Stiles, who... ► Artikel lesen | |
| BIOGEN | 145,35 | -3,96 % | Stoke, Biogen Present Positive Long-Term Results For Zorevunersen In Dravet Syndrome | WESTON (dpa-AFX) - Stoke Therapeutics, Inc. (STOK) and Biogen Inc. (BIIB) on Friday reported positive long-term data from the Phase 1/2a and open-label extension studies evaluating zorevunersen... ► Artikel lesen | |
| ILLUMINA | 114,14 | +0,42 % | Illumina, Inc.: Illumina Reports Financial Results for Third Quarter of Fiscal Year 2025 | Revenue of $1.08 billion for Q3 2025, flat compared to Q3 2024 on both a reported and constant currency basis
GAAP operating margin of 21.0% and non-GAAP operating... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 49,600 | +0,81 % | CRISPR Therapeutics stock rating reiterated at Market Outperform by Citizens | ||
| AAP IMPLANTATE | 1,370 | 0,00 % | EQS-Adhoc: aap Implantate AG: Barkapitalerhöhung | EQS-Ad-hoc: aap Implantate AG / Schlagwort(e): Kapitalerhöhung/Kapitalmaßnahme
aap Implantate AG: Barkapitalerhöhung
04.12.2025 / 13:07 CET/CEST
Veröffentlichung einer Insiderinformation... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,860 | -0,53 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Third Quarter 2025 Financial Results and Recent Business Highlights | Completed rolling Biologics License Application (BLA) submission seeking accelerated approval for lead candidate INO-3107; requested priority review
Expect... ► Artikel lesen | |
| OCUGEN | 1,030 | -0,63 % | Ocugen Provides Business Update with Third Quarter 2025 Financial Results | Phase 2/3 OCU410ST GARDian3 pivotal confirmatory trial is progressing toward 1H 2027 Biologics License Application (BLA) filing with 50% enrollment completed to date European Medicines Agency (EMA)... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 0,435 | +1,30 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy | RICHMOND, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the U.S. Food and Drug Administration (FDA) has granted... ► Artikel lesen |
Das Unternehmen MIRA PHARMACEUTICALS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +2,56 % bei einem Aktienkurs von 1,200 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MIRA PHARMACEUTICALS INC finden Sie auf Wallstreet Online.